The Latest Updates from ReSPECT Clinical Trials

Last week, CNSide® Medical Director Jonathan Stein, PhD, HCLD(ABB) presented at BioHouston’s October Life Science event — joining Houston’s growing network of researchers, entrepreneurs, and clinicians driving the future of biotech innovation. The discussion centered...

Did you know that as many as 5% to 20% of people with advanced breast cancer may eventually develop leptomeningeal metastases (LM) — also known as leptomeningeal disease (LMD)? LM occurs when cancer cells spread to the membranes (meninges) that surround the brain and...

Today marks Metastatic Breast Cancer Awareness Day — a time to honor those living with stage IV breast cancer, remember those we’ve lost, and reaffirm our shared commitment to ending the disease. While significant progress has been made in early-stage breast cancer...

Leptomeningeal metastases (LM) occur when cancer spreads to the delicate membranes surrounding the brain and spinal cord — a complication that affects thousands of patients each year. Because LM often develops silently and can be difficult to detect through standard...

Plus Therapeutics, Inc. (Nasdaq: PSTV) today announced it has received an additional $1.9 million advance payment from the Cancer Prevention and Research Institute of Texas (CPRIT) — the second-largest public cancer research funder globally. This latest payment is...

Last month, several of the world’s leading experts in leptomeningeal metastases (LM) came together at the American Society of Clinical Oncology (ASCO) / Society for Neuro-Oncology (SNO) CNS Metastases Conference to share insights, research, and clinical updates on...

Last week, the leadership teams of Plus Therapeutics and CNSide Diagnostics came together onsite at the SNO/ASCO 2025 CNS Metastases Conference to advance the dialogue on leptomeningeal metastases (LM). LM Symposium The jointly sponsored LM presentation and panel...

The Leptomeningeal Cancer Foundation is hosting an important webinar on Thursday, August 21, 2025 at 11 AM PDT / 2 PM EDT, featuring two leading oncologists: Dr. Seema Nagpal – neuro-oncologist Dr. Mohana Roy – thoracic oncologist Date & Time: Thursday, August 21,...

Plus Therapeutics (NASDAQ: PSTV) announced positive data from the ReSPECT-LM Phase 1 single dose escalation clinical trial, presented at the podium during the Society for Neuro-Oncology (SNO) / American Society of Clinical Oncology (ASCO) CNS Metastases Conference....

Plus Therapeutics (NASDAQ: PSTV) presented encouraging data from a retrospective analysis of the CNSide® Cerebrospinal Fluid (CSF) Assay Platform at the 2025 Society for Neuro-Oncology (SNO) / American Society of Clinical Oncology (ASCO) CNS Metastases Conference in...

Leptomeningeal Metastases (LM) is a devastating complication of advanced cancers, where cancer cells spread to the cerebrospinal fluid and leptomeninges of the brain and spinal cord. Research and collaboration are critical to improving outcomes for patients facing...